Autologous Bone Marrow Transplantation - Blog Science Connections

More documents

Recommendations

Info

0) O) .2 '55 o c O) o o Q. c o + + + + + + + + + + + r- T- CM eo «D • TtoqqqqTf ó^óoiiriiooisoisdcoiíJw CIKO^NCOeO^OCOt-^r-OliococorrrcctrtririrtrirírDcoc 0-000-000-0-0.00-00-0. CM q w N s olio diri^ddo co „ o CM T~ ce oc O Q. •S o i i? o • E = , >>> = = = = s> = = - >> s >>=>>> CO co O 1 s m| < o> c o O) a> T3 c 3 (A ra Q. CO u o o E oo c I I I I I II I I I I I I I I I I I I I | o. | a. | 0.0. | cococM-^CM^co^tTtococjjinm I - W T - N C O O M O C O O M O O I I - c o m l i l i l í 0.0-1 | | 0 . oo LO o TÍ CM en x x x x x x oo oo co CM co o m o ~". ¿2 Q C -J ra . - II E S co 3 p co c co k. co Q. c c P E 2 § -i — u k »1 J B ü U- 2 U- 2 2 Ll- 2 u. 2 U- U- ÍE ü. ¡O •>!- 00 CM i-- CS co CM O CO r- o CM co CO co CM co CM CO CM CM CM ra .9 o CM co m co r~- co CO O CM co LO oo r~- co O) o f- T- f- T- 1- CM co ^ ES
3 o + + + + o LO T— T— LO co Tf CO co co CO •t 00 c\¡ LO ai CO co c\i 1^ CM 6 co LO Ti- CM CM , _ 1— 1— 1 3 o 3 C0 a a* 01 co _> co t» CO a S c _ro a co c CO s o S 0) c o 03 10 3 O OI O 3 < CN a> 10 O X &E £L + + + + O) o iq O) o LO Ti; TI- T- q CM cq c\¡ CO o ci Tí y— LO 1^ y— co t—' co LO Ti- Ti- co CM CM CM _l _l_ _l * ce" , . ce ce z z _l z z ü o ca _l _l z" z ü „ TT _ Q o CO LO LO CO 00 © o> co LO co LO" Tl- CO co CM LO ce ce ce QC CC ce QC ce 0. 0. LL ü 0- ü a. LL o LL co Tl- CO CO O) co r~ o LO CM co LO LO co TI TI T* CM Ti- *~ T— T— *~ CM CO CO CM O) o LO CM LO o> co o CO co LO co co co O) T— co co co ("- LO CM CM w v— co CM CM C0 CM LO CM T— * - c — > > > — > > — > > — I I I I M I I 0. 0. | 1 0 . | 1 a. o. cu CM CM c CO O co i— T- o V - X X r¡ X X CO CO X O O 4-* X X LO CM T— | | 3 CO 00 1 ce 5 2 cé 00 2 m co ü ü _i _i Q o \ _i _l O O ^ O O Q ü O O Q o _i _i Z> _i _i 0. _l _i _i CL _l O Q zoo Z Q o a O Q 5 CQ ir C CO E
Page 1:
Autologous Bone Marrow Transplantat
Page 5 and 6:
Page 7:
To our colleagues, Drs. R. Lee Clar
Page 10 and 11:
via ABMT Autologous Bone Marrow Tra
Page 12 and 13:
X ABMT Pharmacological Manipulation
Page 14 and 15:
XII ABMT C. INTERNATIONAL RANDOMIZE
Page 16 and 17:
xiu ABMT Session IV - Breast Cancer
Page 18 and 19:
xui ABMT Panel Discussion: Session
Page 20 and 21:
xuiii ABMT Effect of Interleukin 2
Page 23:
Acknowledgments The publication of
Page 27 and 28:
Page 29 and 30:
AML in First Remission 5 performed
Page 31:
AML in First Remission 7 than 50% o
Page 34 and 35:
10 BAVC + ABMT in Patients With AML
Page 36 and 37:
BAVC + ABMT in Patients With AML in
Page 38 and 39:
14 BAVC + ABMTin Patients With AML
Page 40 and 41:
16 Purged ABMT in CR of Acute Leuke
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
24 First-Remission Autograft forAML
Page 50 and 51:
Page 52 and 53:
Page 55 and 56:
Page 57:
Transplantation in CRI AML 33 DISCU
Page 60 and 61:
36 ABMT in ALL compared the results
Page 62 and 63:
38 ABMT in ALL were administered un
Page 64 and 65:
40 ABMT in ALL CR1 patients receive
Page 66 and 67:
42 ABMT in ALL 19. Rizzoli V, Mango
Page 68 and 69:
44 ABMTin CRI program in CR1 is the
Page 70 and 71:
46 ABMTin CRI RESULTS The AML inves
Page 73 and 74:
Leukemia: First Remission K A. Dick
Page 75 and 76:
Panel Discussion: Session IA 51 DR.
Page 77:
IB. Clinical Studies in Second- or
Page 80 and 81:
56 ABMTIn CR2 RESULTS OF VARIOUS TR
Page 82 and 83:
58 ABMTIn CR2 antibodies; for non-T
Page 84 and 85:
60 ABMT in Acute Nonlymphocytic Leu
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
70 ABMT in AML With Monoclonal Anti
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
80 Mafosfamide Purging in Leukemia
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 113 and 114:
Page 115 and 116:
ABMT in CR2 Pediatric ALL 91 follow
Page 117 and 118:
Ex Vivo Use of Monoclonal Antibodie
Page 119 and 120:
Ex Vivo Marrow Purging 95 Table 1.
Page 121 and 122:
De Viuo Marrow Purging 97 WBC-f- AN
Page 123 and 124:
Conditioning Regimens Before Bone M
Page 125 and 126:
Conditioning Regimens in AML 101 Le
Page 127:
Conditioning Regimens in AML 103 co
Page 130 and 131:
106 Double (Jnpurged ABMT in Leukem
Page 132 and 133:
108 Double Unpurged ABMT in Leukemi
Page 134 and 135:
770 Double (Jnpurged ABMT in Leukem
Page 136 and 137:
7/2 Double Autografting in Acute Le
Page 138 and 139:
114 Double Autografting in Acute Le
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
120 Recovery After 4-Hydroperoxycyc
Page 146 and 147:
122 Recovery After 4-Hydroperoxycyc
Page 149 and 150:
Page 151 and 152:
Panel Discussion: Session IB 127 di
Page 153:
Panel Discussion: Session IB 129 tu
Page 157 and 158:
Magnetic Affinity Colloid Eliminati
Page 159 and 160:
Magnetic Separation of Marrow Cells
Page 161 and 162:
Page 163 and 164:
*r r- r» u. >>• O S ^ CO ai a> C
Page 165 and 166:
Page 167 and 168:
4-Hydroperoxycyclophosphamide and V
Page 169 and 170:
Chemopurging 145 incubation, the ce
Page 171 and 172:
Chemopurging 147 To date, four pati
Page 173 and 174:
Chemopurging 149 4-HC + VCR IC75 AM
Page 175 and 176:
Decontaminating Bone Marrow With Me
Page 177 and 178:
Merocyanine 540 Marrow Decontaminat
Page 179 and 180:
Merocyanine 540 Marrow Decontaminat
Page 181 and 182:
CALLA-Negative Clonogenic Cultures
Page 183 and 184:
CALLA-Negatiœ Clonogenic BCell ALL
Page 185:
CALLA-Negative Clonogenic BCell ALL
Page 188 and 189:
164 Acetaldophosphamide Ex Vivo Che
Page 190 and 191:
766 Acetaldophosphamide Ex Vivo Che
Page 192 and 193:
168 Acetaldophosphamide Ex Viuo Che
Page 195 and 196:
Detecting Residual Disease in Bone
Page 197 and 198:
Page 199:
Page 202 and 203:
178 Pharmacological Manipulation an
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 211:
ID. Chronic Myelogenous Leukemia
Page 214 and 215:
190 CML Chronic Phase Autografting
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
196 CML Blast Crisis Autografting e
Page 223 and 224:
Autologous Transplantation of Phila
Page 225 and 226:
Autografting in Chronic Granulocyti
Page 227:
Autografting in Chronic Granulocyti
Page 230 and 231:
206 Panel Discussion: Session ID DR
Page 233 and 234:
Natural History of Relapsed Hodgkin
Page 235 and 236:
ABMT in Hodgkin's Disease 211 50%.
Page 237 and 238:
ABMTin Hodgkin, 's Disease 213 (62%
Page 239 and 240:
ABMT in Hodgkin's Disease 215 LLLLL
Page 241 and 242:
Updated Results of CBV and Autologo
Page 243 and 244:
CBV and ABMT in Hodgkin's Disease 2
Page 245:
CBV and ABMT in Hodgkin 's Disease
Page 248 and 249:
224 Chemotherapy and ABMT in Hodgki
Page 250 and 251:
226 Chemotherapy and ABMTin Hodgkin
Page 252 and 253:
Page 254 and 255:
Page 256 and 257: 232 ABMT for Advanced Hodgkin's Dis
Page 258 and 259: 234 ABMTfor Advanced Hodgkin's Dise
Page 261 and 262: Hodgkin's Disease J. O. Armitage an
Page 263 and 264: Panel Discussion: Session IIA 239 D
Page 265: IIB. Non-Hodgkin's Lymphoma
Page 268 and 269: 244 Salvage Chemotherapy for Lympho
Page 270 and 271: 246 Salvage Chemotherapy for Lympho
Page 273 and 274: Autologous Bone Marrow Transplantat
Page 275 and 276: ABMT in Burkitt's Lymphoma 251 Tabl
Page 277 and 278: ABMT in Burkitt's Lymphoma 253 medi
Page 279 and 280: ABMT in Burkitt's Lymphoma 255 Heal
Page 281 and 282: ABMT in Burkitt's Lymphoma 257 •
Page 283 and 284: ABMT in Burkitt's Lymphoma 259 init
Page 285: ABMT in Burkitt's Lymphoma 261 11.
Page 288 and 289: 264 Myeloma Biology and Therapy hig
Page 290 and 291: 266 Myeloma Biology and Therapy mon
Page 292 and 293: 265 Myeloma Biology and Therapy 5.
Page 294 and 295: 270 BMT in Relapsed Diffuse Large C
Page 300 and 301: 276 Transplantation for Malignant L
Page 303 and 304: Optimum Timing of Autologous Bone M
Page 305: ABMT Timing in Lymphoma 281 PATIENT
Page 309 and 310: ABMT Timing in Lymphoma 285 RESULTS
Page 311 and 312: co co I I I I I I I I I I 2 2 2 CD
Page 313 and 314: ABMT Timing in Lymphoma 289 Median
Page 315 and 316: ABMT Timing in Lymphoma 291 in a mi
Page 317 and 318: ABMT Timing in Lymphoma 293 Develop
Page 319: ABMT Timing in Lymphoma 295 53. Sto
Page 322 and 323: 298 Treatment Strategies for NHL PA
Page 324 and 325: 300 Treatment Strategies for NHL 10
Page 326 and 327: 302 Treatment Strategies for NHL 2)
Page 328 and 329: 304 Treatment Strategies for NHL al
Page 330 and 331: 306 Treatment Strategies for NHL 31
Page 332 and 333: 308 Panel Discussion: Session IIB m
Page 335: IIC. International Randomized Study
Page 338 and 339: 314 Proposed International Adult Ly
Page 356 and 357:
332 Proposed International Adult Ly
Page 359 and 360:
International Randomized Trial in N
Page 361 and 362:
International NHL Trial 337 dispari
Page 363 and 364:
International NHL Trial 339 cannot
Page 365 and 366:
International NHL Trial 341 ORGANIZ
Page 367 and 368:
Lymphoma T. Philip and G. Spitzer,
Page 369:
IID. Purging and Detection
Page 372 and 373:
348 Chemoimmunoseparation of T Lymp
Page 374 and 375:
350 Chemoimmunoseparation of T Lymp
Page 376 and 377:
352 Burkitt's Lymphoma Purging Assa
Page 378 and 379:
354 Burkitts Lymphoma Purging Assay
Page 380 and 381:
356 Burkitt's Lymphoma Purging Assa
Page 382 and 383:
358 Burkitts Lymphoma Purging Assay
Page 384 and 385:
360 Purging Methods in Burkitt's Ly
Page 386 and 387:
Page 388 and 389:
Page 390 and 391:
366 Leukemia Cell Sensitivity to Im
Page 392 and 393:
368 Leukemia Cell Sensitivity to Im
Page 394 and 395:
370 Leukemia Cell Sensitiuity to Im
Page 396 and 397:
372 Panel Discussion: Session IID D
Page 399 and 400:
Page 401 and 402:
ABMTfor Neuroblastoma 377 sedimenta
Page 403 and 404:
ABMT for Neuroblastoma 379 EX VIVO
Page 405 and 406:
ABMTfor Neuroblastoma 381 PATIENTS
Page 407 and 408:
Repeated High-Dose Chemotherapy Fol
Page 409 and 410:
ABMT in Metastatic Neuroblastoma 38
Page 411 and 412:
Page 413 and 414:
Page 415:
ABMT in Metastatic neuroblastoma 39
Page 418 and 419:
394 Clnpurged ABMTfor Neuroblastoma
Page 420 and 421:
396 Unpurged ABMTfor Neuroblastoma
Page 422 and 423:
398 Unpurged ABMTfor Neuroblastoma
Page 425 and 426:
ENSG 1—Randomized Study of High-D
Page 427 and 428:
High-Dose Melphalan in Neuroblastom
Page 429:
High-Dose Melphalan in Neuroblastom
Page 432 and 433:
408 ABMTin 65 Patients With Neurobl
Page 434 and 435:
410 ABMT in 65 Patients With. Neuro
Page 436 and 437:
Page 438 and 439:
Page 440 and 441:
416 ABMTin 65 Patients With neurobl
Page 443 and 444:
A Single Institution's Experience o
Page 445 and 446:
ABMT in Neuroblastoma 421 procedure
Page 447:
ABMT in Neuroblastoma 423 therapies
Page 450 and 451:
426 Purged Marrow Engraftment in Ne
Page 452 and 453:
Page 454 and 455:
Page 457 and 458:
Digital Image Analysis System for D
Page 459 and 460:
Digital Image Analysis System 435 d
Page 461 and 462:
Digital Image Analysis System 437 c
Page 463 and 464:
Digital Image Analysis System 439 C
Page 465:
Digital Image Analysis System 441 1
Page 468 and 469:
444 Immune-magnetic Purging ofBurki
Page 470 and 471:
Page 472 and 473:
Page 474 and 475:
450 Panel Discussion: Session III W
Page 476 and 477:
452 Panel Discussion: Session III e
Page 479 and 480:
High-Dose Chemotherapy Intensificat
Page 481 and 482:
High-Dose Chemotherapy and ABMT in
Page 483 and 484:
Page 485 and 486:
Page 487:
Page 490 and 491:
466 Treatment Strategies in Breast
Page 492 and 493:
Page 494 and 495:
Page 496 and 497:
10 CO 0) I- m c o a. a. 3 W ? o k_
Page 498 and 499:
Page 500 and 501:
476 Phase I and II Studies of Alkyl
Page 502 and 503:
Page 504 and 505:
Page 506 and 507:
482 High-Dose Therapy and ABMT in B
Page 508 and 509:
484 High-Dose Therapy and ABMT in B
Page 510 and 511:
486 Immunodetection of Breast Carci
Page 513 and 514:
Page 515 and 516:
ABMTfor Breast Cancer 491 only adju
Page 517 and 518:
ABMT for Breast Cancer 493 Table 3.
Page 519:
ABMTfor Breast Cancer 495 4. Eder J
Page 522 and 523:
498 Occult Breast Cancer Cells in M
Page 524 and 525:
Page 526 and 527:
Page 528 and 529:
504 Panel Discussion: Session IV DR
Page 530 and 531:
506 Panel Discussion: Session IV a
Page 533 and 534:
Detection of Bone Marrow Metastases
Page 535 and 536:
Tumor Cell Detection 511 Two separa
Page 537:
Tumor Cell Detection 513 immunofluo
Page 540 and 541:
516 Etoposide and Cisplatin for Lun
Page 542 and 543:
Page 544 and 545:
Page 547 and 548:
Lung Cancer G. Spitzer and H. Lazar
Page 549 and 550:
Panel Discussion: Session V 525 com
Page 551:
Panel Discussion: Session V 527 col
Page 555 and 556:
Treatment of Advanced Melanoma With
Page 557 and 558:
ABMT in Melanoma 533 Table 1. Three
Page 559 and 560:
ABMT in Melanoma 535 mg/m 2 ). The
Page 561 and 562:
Melanoma/ Sarcoma/ Carcinoma R. Ben
Page 563 and 564:
Panel Discussion: Session VI 539 re
Page 565:
VII. Brain Cancer
Page 568 and 569:
544 Carmustine and ABMT for Maligna
Page 570 and 571:
546 Carmustine and ABMTfor Malignan
Page 573 and 574:
Pilot Study of High-Dose Carmustine
Page 575 and 576:
High-Dose Carmustine and Transplant
Page 577 and 578:
Page 579 and 580:
Page 581 and 582:
High-Dose Chemotherapy With Autolog
Page 583 and 584:
High-Dose Therapy of CNS Gliomas Ta
Page 585 and 586:
High-Dose Therapy of CHS Gliomas 56
Page 587:
High-Dose Therapy of CHS Gliomas 56
Page 590 and 591:
566 Panel Discussion: Session VII A
Page 593:
VIII. New Regimens
Page 596 and 597:
572 Clinical Intensification Regime
Page 598 and 599:
574 Clinical Intensification Regime
Page 600 and 601:
Clinical Intensification Regimens f
Page 602 and 603:
Clinical Intensification Regimens f
Page 605 and 606:
High-Dose Busulfan and Cyclophospha
Page 607 and 608:
Busulfan + Cyclophosphamide in Chil
Page 609 and 610:
Page 611 and 612:
Page 613 and 614:
The Intensive Use of Carmustine Wit
Page 615:
Intensive Use ofCarmustine 591 6. P
Page 618 and 619:
594 BEAM: Cytoreductive Regimen for
Page 620 and 621:
596 BEAM: Cytoreductiue Regimen for
Page 622 and 623:
Page 624 and 625:
Page 626 and 627:
602 Total Body Irradiation, Cytarab
Page 628 and 629:
604 Total Body Irradiation, Cytarab
Page 630 and 631:
606 Panel Discussion: Session VIII
Page 633 and 634:
Herpesvirus Infections After Autolo
Page 635 and 636:
Herpesvirus Infections 611 Table 2.
Page 637:
Herpesvirus Infections 613 contrast
Page 640 and 641:
616 Peripheral Stem Cell Transplant
Page 642 and 643:
Page 644 and 645:
CO ^ CO COi-t'ycOi-T-CO O E « to T
Page 646 and 647:
Page 648 and 649:
fc CD rr ^ O < c E + o — ce S O O
Page 650 and 651:
o E ra o CD .Q Û ra co CL o E o 15
Page 652 and 653:
Page 654 and 655:
Page 656 and 657:
Page 658 and 659:
634 Toxic Deaths in ABMT PATIENTS A
Page 660 and 661:
636 Toxic Deaths in ABMT Table 2. D
Page 662 and 663:
638 Toxic Deaths in ABMT defined an
Page 664 and 665:
640 Infectious Complications ofABMT
Page 666 and 667:
Page 668 and 669:
Page 671 and 672:
Infectious Complications of Autolog
Page 673 and 674:
Infections in ABMT 649 Table 1. ABM
Page 675 and 676:
Infections in ABMT 651 herpes simpl
Page 677 and 678:
Newer Antibiotic Regimens in Cancer
Page 679 and 680:
Antibiotics in Cancer Patients 655
Page 681:
Antibiotics in Cancer Patients 657
Page 684 and 685:
660 Amphotericin B for Neutropenic
Page 686 and 687:
662 Amphotericin B for Neutropenie
Page 688 and 689:
664 Amphotericin B for Neutropenie
Page 690 and 691:
666 IVIg in ABMT in autologous tran
Page 692 and 693:
668 IVlg in ABMT 25. Neiman PE, Ree
Page 694 and 695:
670 Natural Killer Cells and Transp
Page 696 and 697:
672 Natural Killer Cells and Transp
Page 699 and 700:
Autologous Transplantation of Circu
Page 702 and 703:
678 Transplantation of Circulating
Page 705 and 706:
Restoration of Hematopoietic Functi
Page 707 and 708:
Peripheral Stem Cell Transplants 68
Page 709:
Peripheral Stem Cell Transplants 68
Page 712 and 713:
688 Peripheral Blood Stem Cell Tran
Page 714 and 715:
Page 716 and 717:
Page 718 and 719:
694 Bronchoscopy in Marrow Transpla
Page 720 and 721:
696 Bronchoscopy in Marrow Transpla
Page 722 and 723:
698 T Lymphocyte CFU After ABMT cer
Page 724 and 725:
700 T Lymphocyte CFCI After ABMT RE
Page 726 and 727:
702 T Lymphocyte CFU After ABMT CMV
Page 729 and 730:
Supportive Therapy H. Vriesendorp a
Page 731:
X. Molecular Biology
Page 734 and 735:
770 Human ADA in Monkeys years in a
Page 736 and 737:
7/2 Human ADA in Monkeys supernatan
Page 738 and 739:
714 Human ADA in Monkeys Number of
Page 740 and 741:
776 Human ADA in Monkeys primate ma
Page 742 and 743:
718 Electric Field-Mediated DMA Tra
Page 744 and 745:
720 Electric Field-Mediated DNA Tra
Page 747 and 748:
Aberrant Gene Expression in Acute M
Page 749 and 750:
+ z + + + les •ras a z E i ü (0
Page 751 and 752:
Aberrant Gene Expression in AML 727
Page 753:
Aberrant Gene Expression in AML 729
Page 756 and 757:
732 Clonal Detection of Remission p
Page 758 and 759:
734 Clonal Detection of Remission K
Page 760 and 761:
736 Clonal Detection of Remission 3
Page 763 and 764:
Summary D. W. van Bekkum Attempts t
Page 765 and 766:
Summary 741 T cell-depleted bone ma
Page 767 and 768:
Summary 743 hybridization technique
Page 769:
Summary 745 GENETIC THERAPY The las
Page 772 and 773:
748 Concluding Remarks time of the
Page 774 and 775:
750 Contributors and Participants F
Page 776 and 777:
Page 778 and 779:
754 Contributors and Participants P
Page 780 and 781:
756 Contributors and Participants A
Page 782 and 783:
758 Contributors and Participants P
Page 784 and 785:
Page 786 and 787:
762 Contributors and Participants H
Page 788 and 789:
764 Contributors and Participants A
Page 790 and 791:
766 Contributors and Participants G
Page 792 and 793:
Page 794 and 795:
770 Contributors and Participants S
Page 796 and 797:
772 Contributors and Participants C
Page 798 and 799:
Page 800:
776 Contributors and Participants D
show all

Autologous Bone Marrow Transplantation - Blog Science Connections

Create successful ePaper yourself

Delete template?

Save as template?